Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sierra Oncology Inc (SRRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 153,239
  • Shares Outstanding, K 52,300
  • Annual Sales, $ 0 K
  • Annual Income, $ -47,867 K
  • 36-Month Beta 2.76
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.43

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.80 +62.78%
on 11/09/17
3.41 -14.08%
on 12/04/17
+1.00 (+51.81%)
since 11/08/17
3-Month
1.45 +102.07%
on 09/12/17
3.41 -14.08%
on 12/04/17
+1.40 (+91.50%)
since 09/08/17
52-Week
1.10 +166.36%
on 06/19/17
3.41 -14.08%
on 12/04/17
+1.41 (+92.76%)
since 12/08/16

Most Recent Stories

More News
Sierra Oncology Reports Third Quarter Results

- Chk1 inhibitor SRA737 Monotherapy trial expanded to eight leading centers across the UK -- On track to provide planned SRA737 Program Update in February 2018 - - $107.8 million cash expected to fund...

SRRA : 2.93 (+3.17%)
Sierra Oncology Reports Third Quarter Results

Chk1 inhibitor SRA737 Monotherapy trial expanded to eight leading centers across the UK - - On track to provide planned SRA737 Program Update in February 2018 - - $107.8 million cash expected to fund...

SRRA : 2.93 (+3.17%)
Sierra Oncology to Present at the Jefferies 2017 London Healthcare Conference

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 4:00 p.m. GMT on November 16, 2017 -

SRRA : 2.93 (+3.17%)
Sierra Oncology to Present at the Jefferies 2017 London Healthcare Conference

"Beyond PARP - Next Generation DDR Therapeutics" scheduled for 4:00 p.m. GMT on November 16, 2017 -

SRRA : 2.93 (+3.17%)
Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy

- SRA737 demonstrates synergy with replication stress-inducing agents -- SRA737 plus gemcitabine efficacious in gemcitabine-resistant tumor models -- SRA737 potentiated by novel sub-therapeutic gemcitabine...

SRRA : 2.93 (+3.17%)
Sierra Oncology Reports Preclinical Data for its Chk1 Inhibitor SRA737 Supporting its Ongoing Clinical Development Strategy

SRA737 demonstrates synergy with replication stress-inducing agents -- SRA737 plus gemcitabine efficacious in gemcitabine-resistant tumor models -- SRA737 potentiated by novel sub-therapeutic gemcitabine...

SRRA : 2.93 (+3.17%)
Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors

Dr. Allen, key contributor in the advancement of PARP inhibitors, to support Sierra in developing next-generation DDR therapeutics -

SRRA : 2.93 (+3.17%)
CLVS : 62.15 (+4.47%)
EPZM : 13.25 (+1.92%)
Sierra Oncology Appoints Dr. Andrew Allen to its Board of Directors

- Dr. Allen, key contributor in the advancement of PARP inhibitors, to support Sierra in developing next-generation DDR therapeutics -

SRRA : 2.93 (+3.17%)
CLVS : 62.15 (+4.47%)
EPZM : 13.25 (+1.92%)
Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017

Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents, including potentiation by novel low-dose gemcitabine combination, in preclinical models of cancer...

SRRA : 2.93 (+3.17%)
Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017

- Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents, including potentiation by novel low-dose gemcitabine combination, in preclinical models of cancer...

SRRA : 2.93 (+3.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central...

See More

Key Turning Points

2nd Resistance Point 3.22
1st Resistance Point 3.07
Last Price 2.93
1st Support Level 2.80
2nd Support Level 2.68

See More

52-Week High 3.41
Last Price 2.93
Fibonacci 61.8% 2.53
Fibonacci 50% 2.26
Fibonacci 38.2% 1.98
52-Week Low 1.10

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.